Torrent Pharma, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and today is ranked amongst the leaders in the therapeutic segment of Cardiovascular (CV) and Central Nervous System (CNS). It has also achieved a significant presence in Gastro-intestinal, Diabetology, Anti-infective, Pain Management, Gynaecology, and Paediatric segments. Recently we have also forayed into the therapeutic segment of Oncology and Rheumatology.
Torrent Pharma's competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in over 40 countries.
The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market.
Torrent Pharma started international acquisitions in 2005 with 90-year-old Heumann from Pfizer to enter the German market. Later on, purchased ANDA of Monocycline from Ranbaxy for the US Market in 2015.
In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility.
Torrent Pharma is committed towards “not just healthcare but lifecare.”